These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 35660117)

  • 21. Efficacy of more intensive lipid-lowering therapy on cardiovascular diseases: a systematic review and meta-analysis.
    Hsu HY; Lin CJ; Lee YS; Wu TH; Chien KL
    BMC Cardiovasc Disord; 2020 Jul; 20(1):334. PubMed ID: 32660417
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lipid control in the management of type 2 diabetes mellitus: a clinical practice guideline from the American College of Physicians.
    Snow V; Aronson MD; Hornbake ER; Mottur-Pilson C; Weiss KB;
    Ann Intern Med; 2004 Apr; 140(8):644-9. PubMed ID: 15096336
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prevalence and management of hypercholesterolemia in France, the Esteban observational study.
    Blacher J; Gabet A; Vallée A; Ferrières J; Bruckert E; Farnier M; Olié V
    Medicine (Baltimore); 2020 Dec; 99(50):e23445. PubMed ID: 33327276
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cholesterol: until which age 'the lower the better'?
    Marchionni N; Orso F
    Monaldi Arch Chest Dis; 2016 Jun; 84(1-2):749. PubMed ID: 27374051
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Under-use of appropriate blood pressure-lowering and lipid-lowering therapy in the Busselton baby boomer population.
    Yiu W; Knuiman M; Wallace H; Hung J
    Aust J Gen Pract; 2019 Dec; 48(12):883-889. PubMed ID: 31774993
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Statins in primary prevention of cardiovascular disease - should we start while young and healthy?
    Fabijanic D; Luksic B; Ljubkovic M
    Am J Cardiol; 2020 Sep; 130():165-166. PubMed ID: 32624191
    [No Abstract]   [Full Text] [Related]  

  • 27. Heartbeat: impact of suboptimal response to primary prevention statin therapy.
    Otto CM
    Heart; 2019 Jul; 105(13):967-968. PubMed ID: 31201261
    [No Abstract]   [Full Text] [Related]  

  • 28. Hypolipidemic drugs in elderly subjects: Indications and limits.
    Gazzola K; Vigna GB
    Nutr Metab Cardiovasc Dis; 2016 Dec; 26(12):1064-1070. PubMed ID: 27522161
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lipid Management for the Prevention of Atherosclerotic Cardiovascular Disease.
    Michos ED; McEvoy JW; Blumenthal RS
    N Engl J Med; 2019 Oct; 381(16):1557-1567. PubMed ID: 31618541
    [No Abstract]   [Full Text] [Related]  

  • 30. Summaries for patients. Control of lipids in patients with type 2 diabetes: recommendations from the American College of Physicians.
    Ann Intern Med; 2004 Apr; 140(8):I85. PubMed ID: 15096362
    [No Abstract]   [Full Text] [Related]  

  • 31. Risk factors for cardiovascular events in Japanese patients treated with fluvastatin from the long-term event monitoring (LEM) study.
    Morishita R; Itakura H; Nakaya N; Yoshida M; Odawara M; Ichihara A; Mizuno K
    Curr Vasc Pharmacol; 2012 Mar; 10(2):178-86. PubMed ID: 21824105
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evidence supporting primary prevention of cardiovascular diseases with statins: Gaps between updated clinical results and actual practice.
    Bruckert E; Ferrières J
    Arch Cardiovasc Dis; 2014 Mar; 107(3):188-200. PubMed ID: 24613429
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Diet and Cardiovascular Disease Risk Among Individuals with Familial Hypercholesterolemia: Systematic Review and Meta-Analysis.
    Barkas F; Nomikos T; Liberopoulos E; Panagiotakos D
    Nutrients; 2020 Aug; 12(8):. PubMed ID: 32823643
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Decisions regarding cholesterol-lowering therapy in the elderly: the experience in a lipid clinic and a review of the literature].
    Garrido Sanjuán JA; Pía Iglesias G; González Moraleja J; Sesma P
    An Med Interna; 1998 Jun; 15(6):305-10. PubMed ID: 9656510
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Statins in women for primary prevention--is there evidence to back up their use??
    Fenton A; Panay N
    Climacteric; 2010 Oct; 13(5):403-4. PubMed ID: 20738236
    [No Abstract]   [Full Text] [Related]  

  • 36. Prevalence and factors associated with lipid-lowering medications use for primary and secondary prevention of cardiovascular diseases among Malaysians: the REDISCOVER study.
    Baharudin N; Mohamed-Yassin MS; Daher AM; Ramli AS; Khan NMN; Abdul-Razak S
    BMC Public Health; 2022 Feb; 22(1):228. PubMed ID: 35120488
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluating the efficacy and safety of atorvastatin + ezetimibe in a fixed-dose combination for the treatment of hypercholesterolemia.
    Ma YB; Chan P; Zhang Y; Tomlinson B; Liu Z
    Expert Opin Pharmacother; 2019 Jun; 20(8):917-928. PubMed ID: 30908086
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Statins in the primary and secondary prevention of cardiovascular disease in women: facts and myths.
    Virani SS
    Tex Heart Inst J; 2013; 40(3):288-9. PubMed ID: 23914021
    [No Abstract]   [Full Text] [Related]  

  • 39. Compliance with lipid-lowering therapy and its impact on cardiovascular morbidity and mortality.
    Liberopoulos EN; Florentin M; Mikhailidis DP; Elisaf MS
    Expert Opin Drug Saf; 2008 Nov; 7(6):717-25. PubMed ID: 18983218
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Current Perspectives on the Attainment of Lipid Modification Goals Relating to the Use of Statins and Ezetimibe for the Prevention of Cardiovascular Disease in the United Kingdom.
    Reynolds TM; Pottle A; Quoraishi SH
    Vasc Health Risk Manag; 2021; 17():227-237. PubMed ID: 34054297
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.